Association between human immunodeficiency virus infection and stiffness of the common carotid artery

Stroke

Volumn 41, Issue 10, 2010, Pages 2163-2170

  Seaberg, Eric C ^a   Benning, Lorie ^a   Sharrett, A Richey ^a   Lazar, Jason M ^b   Hodis, Howard N ^c   MacK, Wendy J ^c   Siedner, Mark J ^a   Phair, John P ^d   Kingsley, Lawrence A ^e   Kaplan, Robert C ^f  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

atherosclerosis; cardiovascular disease; carotid arteries; epidemiology; HIV

Indexed keywords

ADULT; AGED; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTICLE; ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMMON CAROTID ARTERY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; CHI SQUARE DISTRIBUTION; ECHOGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; VERY ELDERLY; VIROLOGY; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; CAROTID ARTERY, COMMON; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; VIRAL LOAD;

EID: 77958007322     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.583856     Document Type: Article

References (40)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280: 1497-1503.
3. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiebaut R, De WS, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
4. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109: 1603-1608.
5. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet. 1997;350:713-714.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;1:F51-F58.
7. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
8. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62 (Pubitemid 40075680)
9. The SMART Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
10. Bozzette SA, Ake CF, Tam HK, Phippard A, Cohen D, Scharfstein DO, Louis TA. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:338-341.
11. Mercie P, Thiebaut R, Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Morlat P, Ragnaud JM, Dupon M, Malvy D, Bellet H, Lawson-Ayayi S, Roudaut R, Dabis F. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med. 2002;34:55-63.
12. Currier JS, Kendall MA, Zackin R, Henry WK, Ston-Smith B, Torriani FJ, Schouten J, Mickelberg K, Li Y, Hodis HN. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS. 2005;19:927-933.
13. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953-960.
14. Blankenhorn DH, Kramsch DM. Reversal of atherosis and sclerosis. The two components of atherosclerosis. Circulation. 1989;79:1-7.
15. Riley WA, Evans GW, Sharrett AR, Burke GL, Barnes RW. Variation of common carotid artery elasticity with intimal-medial thickness: the ARIC Study. Atherosclerosis Risk in Communities. Ultrasound Med Biol. 1997; 23:157-164.
16. Dolan E, Thijs L, Li Y, Atkins N, McCormack P, McClory S, O'Brien E, Staessen JA, Stanton AV. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension. 2006;47:365-370.
17. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318.
18. Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J. The Multi-center AIDS Cohort Study: retention after 9 1/2 years. Am J Epidemiol. 1995;142:323-330.
19. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
20. Bacon MC, von WV Alden C, Sharp G, Robison E, Hessol N, Gange S, Barranday Y, Holman S, Weber K, Young MA. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12:1013-1019.
21. Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, Hodis HN. Low CD4 + T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS. 2008;22:1615-1624.
22. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
23. Lage SG, Kopel L, Monachini MC, Medeiros CJ, Pileggi F, Polak JF, Creager MA. Carotid arterial compliance in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;74:691-695
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 28, 2008; 1-128. Available at http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL000988.pdf. Accessed February 9, 2010.
25. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:12-22.
26. Schafer JL. Analysis of Incomplete Multivariate Data. New York: Champan and Hall/CRC Press; 1997.
27. Reiss P. How bad is HAART for the HEART? AIDS. 2003;17: 2529-2531.
28. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360: 1747-1748.
29. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De WS, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349:1993-2003.
30. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
31. Lakatta EG, Wang M, Najjar SS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am. 2009;93:583-604.
32. Schillaci G, De Socio GV, Pirro M, Savarese G, Mannarino MR, Baldelli F, Stagni G, Mannarino E. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol. 2005;25:2381-2385.
33. Van Bortel LM, Duprez D, Starmans-Kool MJ, Safar ME, Giannattasio C, Cockcroft J, Kaiser DR, Thuillez C. Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. Am J Hypertens. 2002;15:445-452.
34. McVeigh GE, Morgan DJ, Finkelstein SM, Lemay LA, Cohn JN. Vascular abnormalities associated with long-term cigarette smoking identified by arterial waveform analysis. Am J Med. 1997;102:227-231.
35. Syeda B, Gottsauner-Wolf M, Denk S, Pichler P, Khorsand A, Glogar D. Arterial compliance: a diagnostic marker for atherosclerotic plaque burden? Am J Hypertens. 2003;16(5 Pt 1):356-62.
36. van Leuven SI, Sankatsing RR, Vermeulen JN, Kastelein JJP, Reiss P, Stroes ESG. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart! Curr Opin HIV AIDS. 2008;2:324-331.
37. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS. 2004;18:1037-1041.
38. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008;52:569-576.
39. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation. 2003;107:139-146. (Pubitemid 36070946)
40. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Vella S, Narciso P, Corpolongo A, Andreoni M. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother. 2007;60:724-732.